Vaginal self-sampling is an adequate means of screening HR-HPV types in women not participating in regular cervical cancer screening

Clinical Microbiology and Infection

Volumn 19, Issue 1, 2013, Pages

  Tamalet, C ^a   Le Retraite, L ^b   Leandri, F X ^b   Heid, P ^b   Sancho Garnier, H ^c   Piana, L ^b  

^a TIMONE HOSPITAL   (France)

^b Parc Mure BatA   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

Cervical screening; HPV genotyping; HPV self sampling; Human papillomavirus; Participation rate

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; FEMALE; FEMALE GENITAL TRACT PARAMETERS; FOLLOW UP; HIGH RISK ONCOGENIC HUMAN PAPILLOMAVIRUS INFECTION; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SOCIAL CLASS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL SELF SAMPLING; VIRUS LOAD;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84871617522     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12063     Document Type: Article

References (32)

1. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer 2002; 2: 342-350.
2. Belot A, Grosclaude P, Bossard N et al. Cancer, incidence and mortality in France over the period 1980-2005. Revue d'épidemiologie et de Santé Publique 2008; 56: 159-175.
3. Schaffer P, Sancho-Garnier H, Fender M et al. Cervical cancer screening in France. Eur J Cancer 2000; 36: 2215-2220.
4. Remontet L, Esteve J, Bouvier Am et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidermiol Sante publique 2003; 51: 3-30.
5. Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-1588.
6. Naucler P, Ryd W, Törnberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-1597.
7. Leinonen M, Nieminen P, Kotanierni-Talonen L et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101: 1612-1623.
8. Carcopino X, Henry M, Benmoura D et al. Determination of HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy. J Med Virol 2006; 78: 1131-1140.
9. Gravitt PE, Kovacic MB, Herrero R et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 2007; 121: 2787-2793.
10. Saunier M, Monnier-Benoit S, Mauny F, Dalstein V, Briolat J, Riethmuller D. Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma. J Clin Microbiol 2008; 46: 3678-3685.
11. Dzuba IG, Diaz EY, Allen B et al. The acceptability of self-collected samples for HPV testing vs. The Pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med 2002; 11: 265-274.
12. Piana L, Leandri FX, Jacqueme B et al. Organized cervical cancer screening for underprivileged women. Bull Cancer 2007; 94: 461-467.
13. Tamalet C, Richet H, Carcopino X et al. Testing for Human papillomavirus and measurement of viral load of HPV16 and 18 in self-collected vaginal swabs in women who do not undergo cervical cytological screening in Southern France. J Med Virol 2010; 82: 1431-1437.
14. Stenvall H, Wikstrom I, Wilander E. High prevalence of oncogenic human papillomavirus in women not attending organized cytological screening. Acta Derm Venereol 2007; 87: 243-245.
15. Gyllensten U, Lindell M, Gustafsson I, Wilander E. HPV test shows low sensitivity of Pap Screen in older women. Lancet Oncol 2010; 11: 509-510.
16. ANAES. Conduites à tenir devant une patiente ayant un frottis cervico-uterin anormal. Actualisation 2002. http://www.has-sante.fr.
17. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda system terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119.
18. Gök M, Heideman DAM, Van Kemenade FJ et al. HPV testing on self collected cervicivaginal lavage specimens as screening method for women who do not attend cervical screening cohort study. Br Med J 2010; 340: c1040.
19. Rossi PG, Marsili LM, Camilloni L et al. The effect of self-sampled HPV-testing on participation to cervical cancer screening in Italy: a randomised controlled trial. Br J Cancer 2011; 104: 248-254.
20. Swarewski A, Cadman L, Mesher D et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening-a randomised controlled trial. Br J Cancer 2011; 104: 915-920.
21. Parikh S, Brennan P, Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 2003; 105: 687-691.
22. Sanner K, Wikström I, Strand A, Lindell M, Willander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer 2009; 101: 871-874.
23. Lazcano-Ponce E, Tibor-Lorincz T, Cruz-Valdez A et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011; 338: 1868-1873.
24. Stenvall H, Wikstrom I, Backlund I, Wilander E. Accuracy of HPV testing of vaginal smear obtained with a novel self-sampling device. Acta Obstet Gynecol Scand 2007; 86: 16-21.
25. Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghizoni L. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol 2009; 81: 529-535.
26. Sellors JW, Karwalajtys TL, Kaczorowski JA et al. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ 2002; 167: 871-873.
27. Pretet JL, Jacquard AC, Carcopino X et al. Human papillomavirus genotype distribution in high grade cervical lesions (CIN2/3) in France. EDITH study. Int J Cancer 2008; 122: 424-427.
28. Nielsen A, Kjaer SK, Munk C, Iftner T. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12000 younger and older Danish women. Sex Transm Dis 2008; 35: 276-282.
29. Carcopino X, Henry M, Mancini J et al. Significance of HPV 16 and 18 viral load quantitation in women referred for colposcopy. J Med Virol 2012; 84: 306-313.
30. Spinillo A, Dal bello B, Gardella B et al. Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol 2009; 113: 115-119.
31. Selva L, Gonzalez-Bosquet E, Rodriguez-Plata MT et al. Detection of human papillomavirus infection in women attending a colposcopy clinic. Diagn Microbiol Infect Dis 2009; 64: 416-421.
32. Baay M, Smits E, Tjalma WAA et al. Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer 2004; 108: 258-261.